美国安进地舒单抗多少钱一支？

It can bind and act on RANKL, hindering the binding of RANKL on the surface of osteoclast precursor cells and mature cells, thereby inhibiting the activation and development of osteoclasts, reducing bone resorption, increasing bone density, and is effective in patients with bone metastasis. So, how much does Amgen denosumab cost in the United States?

Desosumab has not yet been included in the medical insurance in China. Overseas, a box of denosumab produced by Amgen in the United States is only about $1,500. Compared with the same period last year, the price of the original research drug sold in China has dropped. Patients in need can purchase medicines abroad or obtain medicines through domestic professional overseas medical service organizations (such as Medical Companion Travel), which can be delivered directly to their homes to ensure authenticity.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

Denosumab has attracted widespread attention as a new treatment modality. GCTB contains two components: multinucleated osteoclast-like giant cells and mononuclear stromal cells. The latter can express RANKL. The RANKL/RANK signaling pathway is the key to initiating the osteoclast process in the pathogenesis of GCTB. Denosumab is a fully human monoclonal antibody with high affinity for RANKL (receptor activator of nuclear factor KB ligand). It inhibits the osteoclast process by blocking this signaling pathway.

In unresectable patients, denosumab resulted in effective long-term disease control, with a 5-year progression-free survival (PFS) rate of 88%. It is an effective drug for bone metastasis after zoledronic acid resistance or adverse reaction intolerance. Denosumab is the first RANKL inhibitor approved by the FDA.